Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,068
datasets available to search
ShareScore release 0.9.0
Dataset results
1,068 results for “PD-1”
AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy
ClinicalTrials.gov study NCT02694822. IPD Sharing: NO. Countries: 1. Publications: 0.
PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine
ClinicalTrials.gov study NCT01441765. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor
ClinicalTrials.gov study NCT03977467. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Electroacupuncture Combined With PD-1 Inhibitor for ECOG2 Advanced NSCLC
ClinicalTrials.gov study NCT07239661. IPD Sharing: NO. Countries: 1. Publications: 0.
Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC)
ClinicalTrials.gov study NCT04808999. IPD Sharing: NO. Countries: 1. Publications: 0.
Electroacupuncture Combined With PD-1 Inhibitor for Elderly Patients With Advanced NSCLC
ClinicalTrials.gov study NCT07086300. IPD Sharing: NO. Countries: 1. Publications: 0.
Efficacy and Safety of Radiotherapy in Oligoprogressive HCC Following First-line PD-1 Therapy
ClinicalTrials.gov study NCT06870942. IPD Sharing: NO. Countries: 1. Publications: 0.
LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma
ClinicalTrials.gov study NCT04577807. IPD Sharing: NO. Countries: 1. Publications: 0.
Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
ClinicalTrials.gov study NCT03737123. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer
ClinicalTrials.gov study NCT03936959. IPD Sharing: NO. Countries: 5. Publications: 0.
Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy
ClinicalTrials.gov study NCT03302247. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV
ClinicalTrials.gov study NCT04007588. IPD Sharing: YES. Countries: 1. Publications: 0.
Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer
ClinicalTrials.gov study NCT06196671. IPD Sharing: UNDECIDED. Countries: 0. Publications: 2.
A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036)
ClinicalTrials.gov study NCT02179918. IPD Sharing: NO. Countries: 1. Publications: 0.
BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With
ClinicalTrials.gov study NCT04284787. IPD Sharing: YES. Countries: 1. Publications: 0.
SBRT + PD-1/PDL-1 Inhibiting Therapy for Advanced Solid Tumors After Dz Control on PD-1/PDL-1 Tx
ClinicalTrials.gov study NCT03220854. IPD Sharing: NO. Countries: 1. Publications: 0.
Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor
ClinicalTrials.gov study NCT03041181. IPD Sharing: NO. Countries: 1. Publications: 0.
Combination of ATG-based Conditioning Regimen and PTCy for GVHD Prevention in Allo-HSCT After PD-1 Blockade
ClinicalTrials.gov study NCT06238245. IPD Sharing: NO. Countries: 0. Publications: 2.
CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
ClinicalTrials.gov study NCT03628716. IPD Sharing: NO. Countries: 1. Publications: 0.
Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours
ClinicalTrials.gov study NCT03697304. IPD Sharing: NO. Countries: 3. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.